Interleukin-10 Therapy—Review of a New Approach

By K. Asadullah, Wolfram Sterry, H. Volk. Pharmacological Reviews, 2003

1,037 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans (2006, background): “To demonstrate that the IL-10-anergized cells are highly enriched in Tr1 cells, cultures are cloned in the presence of a feeder mixture consisting of allogenic PBMC and EBV-LCL and repetitively stimulated through the T-cell receptor.”
Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids (2005, background): “coid treatment increases IL-10,[203] which inhibits Glucocorticoids induce or aggravate diabetes NF-κB activity and affects many immune cells.[204] mellitus and induce arterial hypertension.”
MicroRNAs: the fine-tuners of Toll-like receptor signalling (2011, background): “By contrast, IL-10 seems to have a stimulatory effect on B cells, resulting in enhanced proliferation, differentiation and class-switch recombinatio”
Inflammation and insulin resistance (2008, background): “activity could serve as a potential treatment of insulin resistance [42].”
Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma (2005, background): “So, IL-10 is a potent anti-inflammatory cytokine, which through its suppressive effects on DCs and macrophages, inhibits various inflammatory pathologie”